Efeito de medicamento produzido com cistos de Toxoplasma gondii em camundongos infectados com este protozoário

• Ano de defesa: 2013
• Autor(a) principal: Braga, Caroline Felicio
• Tipo de documento: Dissertação
• Tipo de acesso: Acesso aberto
• Idioma: por
• Instituição de defesa: Universidade Estadual de Maringá; Brasil; Departamento de Ciências Básicas da Saúde; Programa de Pós-Graduação em Ciências da Saúde; UEM; Maringá, PR; Centro de Ciências da Saúde
• Palavras-chave em Português: Toxoplasmose; Toxoplasma gondii; Bioterápicos; Brasil.; Toxoplasmosis; Biotherapic; TGF-b; Brazil.; Ciências da Saúde; Medicina
• Link de acesso: http://repositorio.uem.br:8080/jspui/handle/1/2039

We compared the test blind, controlled, randomized by draw the effect of different dilutions of biotherapic T. gondii. 56 male mice, Swiss, 60 days, were divided into groups according to treatment: BIOT-TG7, BIOT-TG17, BIOT-TG30, BIOT-TG60, BIOT-TG100, IOTTG200, GCInf - infected control group treated with alcohol cereals -7% and GCU- uninfected control group and untreated. The biotherapics were produced according to Brazilian Homeopathic Pharmacopoeia, with macerated mice brain (20 cysts T. gondii/100μL). The animals were treated for three consecutive days prior to infection. For groups BIOT-TG7, BIOT-TG17, BIOT-TG30 and BIOT-TG60 and GCInf 0.1mL/4X/dia was administered on the first day and 2X/day remaining days of treatment. For BIOT-TG100 and BIOT-TG200 was used only 0.1mL/dose / day. At 60 days the animals were infected (strain ME49 cysts 20-T. Gondii), orally. Clinical parameters were evaluated before, during and after administration of biotherapic infection. Tonometry was performed ocular fundoscopy and at 55 days postinfection. Sixty days after infection brain cysts were counted and estimated the number of bradyzoites / cyst. TGF-b was dosed serum (ELISA). Statistical comparison with the Kruskalwallis, 5% significance level. The number of cysts per bradyzoites was lower (p <0.05) for groups BIOT-TG7, BIOT-TG100 and BIOT-TG200 compared to GCInf. The number of cysts tended to decrease in BIOT-TG17 and BIOT-TG200 compared to GCInf. During treatment were observed decrease in water consumption (p = 0.0392) and diet (p = 0.0225) groups BIOT-TG30 and BIOT-TG60 and decreased excreta disposal (p = 0.0021) groups BIOTTG17, and BIOT-TG30, BIOT-TG60, relative to GCInf. There was a mortality rate of one or two animals in groups BIOT-TG7, BIOT-TG17, BIOT-TG30 and BIOT-TG60. After infection were observed weight reduction (p <0.01) in the groups IOT-TG7, BIOT-TG17, BIOT-TG30 and BIOT-TG60 and reduction in the quantity of excreta (p = 0.0284) in thegroups BIOT-TG7 and BIOT-TG30. Animals treated with BIOT-TG7 and BIOT-TG30 showed marked ascites and there was a death in the group BIOT-TG200. In the ocular fundus 80% of group BIOT-TG100 showed no change and 20% had mild subretinal hemorrhage around the optic nerve. In ocular tonometry in the levels of TGF-b there was no difference between groups. The statistical comparison and daily observation clearly shows the difference in effect between biotherapics. The groups BIOT-TG7, BIOT-TG17, BIOT-TG30 and BIOTTG60 had clinical more intense compared to GCInf. The groups treated with higher dilutions BIOT-TG100 and BIOT-TG200 provided benefits more effective, highlighting the BIOTTG200 as the drug of choice for presenting results more satisfactory, deserving further studies.